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Adenosine triphosphate (ATP) is known to induce cell death in T  lymphocytes at 
high extracellular concentrations. CD4+ and CD8+ T  lymphocytes have a differential 
response to ATP, which in mice is due to differences in the P2X7 receptor expression 
levels. By contrast, we observed that the difference in human CD4+ and CD8+ T lym-
phocyte response toward the synthetic ATP-analog BzATP is not explained by a dif-
ference in human P2X7 receptor expression. Rather, the BzATP-induced human P2X7 
receptor response in naïve and immune-activated lymphocyte subtypes correlated 
with the expression of another ATP-binding receptor: the human P2Y11 receptor. In 
a recombinant expression system, the coexpression of the human P2Y11 receptor 
counteracted BzATP-induced human P2X7 receptor-driven lactate dehydrogenase 
release (a marker of cell death) and pore formation independent of calcium signaling. 
A mutated non-signaling human P2Y11 receptor had a similar human P2X7 receptor-in-
hibitory effect on pore formation, thus demonstrating that the human P2X7 receptor 
interference was not caused by human P2Y11 receptor signaling. In conclusion, we 
demonstrate an important species difference in the ATP-mediated cell death between 
mice and human cells and show that in human T lymphocytes, the expression of the 
human P2Y11 receptor correlates with human P2X7 receptor-driven cell death following 
BzATP stimulation.
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inTrODUcTiOn
The adenosine 5'-triphosphate (ATP)-binding receptor P2X7 has been shown to play an important 
role in the regulation of immune cells (1, 2). Binding of extracellular ATP allows the receptor to form 
a cation channel within milliseconds that among other things promotes formation and release of 
various cytokines from innate immune cells (3). At higher ATP concentrations, the P2X7 receptor 
displays the property of pore formation (4). P2X7 receptor pore formation occurs within seconds 
and results in changes in membrane permeability. This change in membrane permeability places the 
Table 1 | Human TaqMan Gene Expression Assay primer/probes (#4331182, 
Life Technologies) showing target gene, the cell samples analyzed using the 
respective primer/probe sets, and their probe numbers.
Target gene cell sample Probe number
P2RY11 HEK-293, GripTite Hs01038858_m1
P2RY11 T lymphocytes Hs00267414_s1
P2RX7 (isoform A and B) HEK-293, GripTite, 
T lymphocytes
Hs00175721_m1
GAPDH HEK-293, GripTite, 
T lymphocytes
Hs99999905_m1
ACTB (β-actin) HEK-293, GripTite, 
T lymphocytes
Hs99999903_m1
B2M (β2-microglobulin) T lymphocytes Hs00984230_m1
EEF1A1 T lymphocytes Hs00265885_g1
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P2X7 receptor as an important mediator of the programmed cell 
death termed pyroptosis, which is characterized as an altruistic 
cell death where cells swell, burst, and die to release cellular con-
tent that attracts other immune cells to continue the fight against 
infections (5).
This type of P2X7 receptor-mediated cell death has been found 
important in mouse lymphocytes, where it regulates the homeo-
stasis of T lymphocyte subpopulations (6). A lower ATP-induced 
calcium signaling has been seen in mouse CD8+ T lymphocytes 
compared to that in CD4+ T lymphocytes. This correlated with 
the level of P2X7 receptor expression (7). In another study, ATP 
resulted in the surface exposure of phosphatidylserine measured 
by annexin V staining in mouse CD4+ cells, but not in CD8+ cells. 
This effect correlated with the protein level of the P2X7 receptor 
(8).
In the present study, we found that CD4+ and CD8+ T lym-
phocytes isolated from human donors showed different P2X7 
receptor activity similar to mouse T lymphocytes. This was seen 
despite similar P2X7 receptor levels in human CD4+ and CD8+ 
T  lymphocytes. We hypothesized that this effect could instead 
be attributed to another ATP-sensing receptor: the P2Y11 recep-
tor. This receptor is a G-protein-coupled receptor (GPCR), and 
stimulation of the receptor results in the activation of adenylyl 
cyclase and phosphatidylinositol pathways (9, 10). As this recep-
tor is not present in mice cells, it offers an alternative mechanism 
for altering human immune cell death. The P2Y11 receptor plays 
a role in various immunomodulatory pathways (11), e.g., it has 
been found that low P2RY11 gene expression correlates with an 
increased ATP-induced cell death in human natural killer cell and 
T  lymphocytes (12) and the P2Y11 receptor delays apoptosis in 
human neutrophils (13). In CD4+, CD8+, and NK cells, stimula-
tion with a P2Y11 receptor agonist NF546 rescues cells from ATP-
induced cell death (12). This suggests that immune cell death in 
the presence of high ATP in humans is controlled not only by 
the level of the P2X7 receptor, as murine data suggest, but by the 
overall balance of ATP-sensing receptors including the P2Y11 
receptor. The human P2Y11 receptor thus represents an important 
target in the regulation of human T lymphocytes. In this paper, we 
provide evidence that P2Y11 receptor inhibits P2X7 receptor pore 
formation but not calcium signaling which occurs independently 
of P2Y11 receptor signaling.
MaTerials anD MeThODs
lymphocyte isolation
Blood from healthy donors was collected under informed writ-
ten consent as approved by the ethical committee of Region 
Hovenstaden, Denmark, under license H-3-2013-054. Peripheral 
blood mononuclear cells (PBMCs) were isolated from buffy coats 
from healthy donors by gradient centrifugation in LymphoPrep 
(#1114740, Axis-Shield). Negative selection was carried out on fresh 
cells with RosetteSep (#15022, #15023, StemCell) or from frozen 
PBMCs using EasySep (#19052, #19053, StemCell). Frozen PBMCs 
were quickly thawed, resuspended in fresh medium, and rested for 
2 h at 37°C before use. Cells were kept in RPMI-1640 (#BE12-702F, 
Lonza)  +  10% fetal bovine serum (FBS) (#S0115, Biochrom). 
Freezing was done in additional 10% FBS and 10% DMSO.
immune activation and gene expression 
Measurement
Transfected cells in 24 wells were harvested and cell pellets stored 
at −80°C before mRNA extraction and gene expression meas-
urements. Primary RosetteSep isolated cells were maintained as 
8 × 105/mL with or without the addition of Dynabeads-Human 
T-Activator CD3/CD28 (#11161D, Gibco, Life Technologies). 
Cell pellets were collected and quickly frozen days 0–3 at −80°C.
mRNA was extracted by RNeasy Mini Kit (#74106, Qiagen). cDNA 
synthesis was carried out using TaqMan Reverse Transcription 
Reagents (#N8080234, Invitrogen, Life Technologies). qPCR 
gene expression was performed using TaqMan Universal PCR 
Master Mix (#4369016, Applied Biosystems, Life Technologies) 
with ACTB (β-actin) and GAPDH as housekeeping genes (list of 
primers shown in Table 1). Two separate primer/probe sets were 
used to analyze P2RY11 expression in primary T  lymphocytes 
and transfected cells, as the primer/probe set used for primary 
cells spanned the 3'-untranslated region of the gene, which was 
not present in the vector. B2M and EEF1A1 genes were used as 
housekeeping genes because GAPDH and ACTB are not stable 
following immune activation (14, 15).
Western blot
Cell pellets were snap-frozen in dry ice and stored at −80°C until 
later use. The cells were lysed in RIPA buffer (#856545, RegionH 
Pharmacy) supplemented with Triton X-100 for a concentration 
of 1% and cOmplete protease inhibitor was added (#11697498001, 
Roche Diagnostics). Samples were stored at −20°C until further 
use. Protein was denatured for 5 min at 95°C in 25% Laemmli 
buffer [0.25  M Tris-HCl (#839847, RegionH Pharmacy), 40% 
glycerol (#104092, Merck Millipore), 20% 2-mercaptoethanol 
(#M-6250, Sigma-Aldrich), 2% sodium dodecyl sulfate (SDS) 
(#L4390, Sigma-Aldrich), 0.01% bromophenol blue (#B-7021, 
Sigma-Aldrich)] before loading into RunBlue SDS Precast 4–20% 
in 12-well 10 × 10 cm gel (#NXG42012, Expedeon) and run in 
RunBlue SDS running buffer (#NXB50500, Expedeon). Protein 
was transferred onto an ethanol-activated Hypond-P membrane 
(#10600057, GE Healthcare Life Sciences) in transfer buffer [Tris-
Gly buffer (#843856, RegionH Pharmacy), 20% ethanol, 0.1% 
SDS (#161-0416, BioRad)]. Blocking solution for unspecific bind-
ing was prepared as 2% Amersham ECL Prime Blocking Reagent 
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(#RPN418V, GE Healthcare Life Sciences) in TBST buffer [TBS 
(#838571, RegionH Pharmacy), 0.1% Tween20], and membranes 
were blocked for 1 h at room temperature (RT) before incubation 
in primary rabbit anti-human P2X7 receptor (#ab109246, Abcam) 
or loading control diluted in TBST buffer with 0.4% blocking 
solution at 4°C overnight. Loading control was 1:5,000 mouse 
anti-β-actin (#A5441, Sigma-Aldrich) with a size of 42  kDa. 
On the following day, membranes were washed three times in 
TBST before shaking for 1 h at RT in 1:40,000 secondary ELC 
donkey HRP-linked anti-rabbit IgG (#NA934V, GE Healthcare 
Life Sciences) or 1:20,000 ELC sheep HRP-linked anti-mouse IgG 
(#NA931V, GE Healthcare Life Sciences) diluted in TBST. After 
washing, membranes were developed with Amersham ECL Select 
Western Blotting Detection Reagent (#RPN2235, GE Healthcare 
Life Sciences) for 5 min at RT and illuminated with chemilumi-
nescence on LAS-4000 system.
Stripping and re-blotting were done with re-blot strong solu-
tion (#2504, Merck Millipore) for 15 min followed by blocking 
and staining with a primary rabbit anti-human P2Y11 receptor 
antibody (#ab183096, Abcam) as described above. This antibody 
has been found suitable for the detection of the P2Y11 receptor in 
Western blotting (16). Loading control staining with anti-β-actin 
was done analog to the above following another round of strip-
ping of the membrane.
Flow cytometry
Peripheral blood mononuclear cells were thawed and rested as 
described above. 106 cells were placed per tube and washed with 
phosphate buffered saline (PBS) (#L0615-500, Biowest), 400 g for 
5 min at 4°C before staining with Fixable Viability Dye eFlouro 
506 (#65-0866, eBioscience) for 20 min at RT. Cells were blocked 
for unspecific binding in PBS with 10% human serum (#H4522, 
Sigma-Aldrich) for 15 min on ice. Then, they were washed with 
PBS and incubated with combinations of extracellular anti-human 
CD3-BV421 (#563798, BD Bioscience), anti-human CD4-FITC 
(#11-0047-42, eBioscience), or CD8-PE-Cy7 (#344712, Nordic 
BioSite) for 30 min at 4°C. The cells were washed in PBS with 0.5% 
human serum before fixation and stained as previously described 
(16). Briefly, human P2Y11 receptor staining was performed on 
unpermeabilized cells with 0.1-µg Lightning Link (#705-0030, 
Innova Biosciences, UK) APC-conjugated 1:100 rabbit anti-human 
P2Y11 receptor antibody (#ab140878, Abcam) against the extracel-
lular part for 30 min. We have previously tested this antibody and 
found it specific for the detection of human P2Y11 over P2Y1 and 
P2Y2 in transfected cells by flow cytometry (16). Flow cytometry 
was done on FACSverse (BD Biosciences, USA), and the FACSuite 
software (BD Biosciences, USA) was used for data analysis.
silencing rna (sirna) Transfection
Cells were transfected with siRNA against P2RY11 (#L-005691-00-
0005) and non-target control #1 (#D-001810-10-05, SMARTpool, 
ON-TARGETplus, Thermo Scientific) using 0.125  nmol on 
2.0 × 106 cells in an Amaxa Nucleofector (Lonza) as previously 
described (17). The cells were following transfection cultured in 
RPMI-1640 containing 2 mM l-glutamine and 100 mg/mL peni-
cillin/streptomycin (Sigma-Aldrich). All cells were supplemented 
with 10% human serum (The Danish National Bloodbank, 
Denmark) and stimulated with Dynabeads-Human T-activator 
CD3/CD28 (#11131D, Thermo Scientific).
cell lines
Human embryonic kidney (HEK-293) cells were maintained in 
culture medium: DMEM (#BE12-604F, Lonza) + 10% FBS + 0.5% 
p/s (#DE17-602E, Lonza) at 37°C, 5% CO2, and humidified air. 
GripTite 293 MSR cell line (a generous gift from Søren Gøgsig 
Faarup Rasmussen, University of Copenhagen, Denmark) is a 
genetically engineered HEK-293 line expressing the human mac-
rophage scavenger receptor for better surface adherence. GripTite 
cells were maintained in culture medium supplemented with 1% 
non-essential amino acid (NEAA) (#M7145, Sigma-Aldrich) 
and 600 µg/mL antibiotic selection agent Geneticin (#10131-019, 
Gibco, Life Technologies) at 37°C, 5% CO2, and humidified air. 
Cells were passaged two to three times per week with trypsin 
(#L0930-100, Biowest) and versene (#15040-066, Gibco, Life 
Technologies).
Plasmids constructs and Transient 
Transfection
Vectors used for transfection were pcDNA3.1 (empty vector), 
eGFP, human P2RX7 in a pcDNA3.1 backbone, human P2RY11 
(#EX-Z1416-M02, GeneCopoeia), and human P2RY11-mCherry 
(EX-Z1416-M56, GeneCopoeia). The C919T mutation was cre-
ated in the P2RY11-mCherry vector using QuikChange Lightning 
Site-Directed Mutagenesis Kit (#210518, Agilent Technologies) 
following the manufacturer’s protocol. Mutation primers were F: 
5'-ggcatgaggccccacatcacctggtag-3' and R: 5'-ctaccaggtgatgtggggc 
ctcatgcc-3' (LGC Biosearch Technologies, Denmark). The mutated 
plasmid construct was sequenced at Eurofins Genomics Sequenc-
ing Department, Germany.
We used a reverse transfection protocol where the cells are 
seeding in wells during transfection or by seeding transfected cells 
into wells to control for transfection efficiency. Cotransfection of 
eGFP was included in the control group in some experiments or 
the application of a vector construct of P2Y11 receptor fused to 
mCherry to visualize successful transfection. The mCherry tag 
changed neither the calcium nor the cyclic adenosine monophos-
phate (cAMP) response of the P2Y11 receptor as shown in Figure 
S1A in Supplementary Material. Also, the gene expression levels 
in cells following transfection were measured to compare gene 
expression levels to rule out group-to-group variation (Figure 
S1B in Supplementary Material).
Transfection of cells for lactate dehydrogenase (LDH) and 
pore formation measurements was carried out by allowing the 
formation of DNA:Lipofectamine complexes in a medium with-
out selection agent for 5 min. DNA:Lipofectamine mixture was 
dissolved to a final concentration of 0.5% Lipofectamine 2000 
Reagent (#11668-019, Invitrogen, Life Technologies) and 1  µg 
DNA/mL. Cells were resuspended in this solution and seeded as 
5 × 104 cells/well poly-d-lysine (#P6407, Sigma)-coated transpar-
ent or black clear bottom 96-well plate or 2.5 × 105 cells/well in 
poly-d-lysine-coated 24-well plate for gene expression. After a 
5-h incubation, the medium was changed to culture medium and 
incubated overnight at 37°C, 5% CO2, and humidified air.
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Cells for calcium imaging were cultured as 9.5 × 105 cells/well 
in a 6-well plate for 24 h. Lipofectamine and DNA were dissolved 
in DMEM + 10% FBS + 1% NEAA for a total of 2 µg DNA/well 
and 0.25% Lipofectamine, respectively, and allowed to transfect 
overnight. Cells were washed in PBS and loosened with versene 
and trypsin and cultured overnight as 3 × 105 cells/well in a black 
clear-bottomed poly-d-lysine-coated 96-well plate before further 
analysis.
cell Death by lDh Measurement
Cells were incubated with the synthetic ATP-analog 3'-O-(4-
benzoyl)benzoyl-ATP (BzATP, #B6396-25MG, Sigma) dissolved 
in water, P2X7 receptor antagonist A740003 (#sc-291774, Santa 
Cruz Biotechnology) dissolved in ethanol, 4,4'-[carbonylbis(imino-
3,1-(4-methyl-phenylene)-carbonylimino)]-bis(naphthalene-
2,6-disulfonic acid) tetrasodium salt (NF340) dissolved in water 
(#3830/10, Tocris) or 1% Triton X-100 (#T9284-500 mL, Sigma-
Aldrich) for 2  h before LDH measurement. EasySep-isolated 
lymphocytes at a concentration of 105 cells/well were incubated 
for 2 h in round-bottomed 96-well plates with various concentra-
tions of the abovementioned compounds before LDH measure-
ment. LDH release was measured using an LDH colorimetric 
assay (#ab102526, Abcam). Absorbance for the culture medium 
without cells was subtracted from the values before calculating 
LDH release. All experiments included a nicotinamide adenine 
dinucleotide standard curve and a positive LDH control supplied 
with the kit.
Pore Formation by YO-PrO-1 Dye Uptake
Twenty-four hours after medium change, transfected cells were 
washed once in dye buffer prepared as Hank’s Balanced Salt 
Solution (HBSS), (#14170112, Gibco, Life Technology) with 0.2% 
YO-PRO-1® Iodide 491/509 (#Y3603, Life Technologies). Plates 
were read with NOVOStar (BMG LABTECH GmbH) microplate 
reader for every 2 min at 489/510 for 8 min before manually add-
ing stimulatory compounds. The plate was then read for 64 min 
every 2  min. Pore formation was assessed by calculating the 
change in fluorescence intensity as Fmax − Fmin.
calcium response by Fluo-4
One day after seeding in 96-well plate, the cells were washed 
with a washing buffer (HBSS (#14065-049, Gibco), 10  mM 
HEPES (#15630-080, Gibco), 2  mM probenecid (#P8761, 
Sigma) (pH =  7.4)) and next incubated in a loading buffer 
(2  µM Fluo-4 AM (#F14201, Molecular Probes, in DMSO), 
0.02% pluronic acid F-127 (#P2443, Sigma, in DMSO) in wash-
ing buffer) for 30 min. Cells were washed and allowed to rest for 
10 min at 37°C in a washing buffer before automatic addition 
of BzATP. The signal was detected using the NOVOStar micro-
plate reader system in a 2-min time span. For each data point, 
the maximal increase in the signal above baseline signal before 
BzATP addition was calculated. The resulting dose–response 
curves were normalized using baseline as 0% signal and signal 
at the highest dose as 100%. Next, the curve was fitted using 
a four-parameter fit of either a sigmoidal dose–response 
curve (one receptor) or a biphasic sigmoidal dose–response 
curve (two receptors). The fitted curves were finally used to 
calculate EC50. All calculations were performed using GraphPad 
Prism 7.
caMP response by elisa
Transfected cells in 96-well plates were lysed for 10 min in 0.1 M 
HCl. Debris was removed by centrifugation  at ≥600  g 5  min. 
The supernatant was analyzed with cAMP ELISA colorimetric 
kit (#ADI-900-066, Enzo Life Sciences) according to manufac-
turer’s protocol. Briefly, the plate was prepared with 50 µL/well 
neutralizing reagent. Blue conjugate and yellow antibody were 
added to each well and incubated for 2 h on a plate shaker. The 
samples were washed three times in a washing buffer before 
the addition of substrate and incubation 1  h without shaking. 
The reaction was stopped and read at 405 nm. For each data point, 
cAMP concentration in pmol/mL was calculated on the basis of 
a standard curve. The resulting dose–response curve was fitted 
using a four-parameter fit of a sigmoidal dose–response curve 
using GraphPad Prism 7.
statistics
All statistical analyses were carried out in GraphPad Prism 7. Gene 
expression in CD4+ and CD8+ T lymphocytes was compared in 
a two-sided t-test. Gene expression changes in CD4+ T lympho-
cytes following in  vitro immune activation were analyzed with 
one-way ANOVA and Dunnett’s post hoc testing against day 0. 
LDH activity in transfected CD8+ T  lymphocytes was analyzed 
with one-way ANOVA and Dunnett’s post hoc testing. The mean 
values from individual donors or experimental runs were used 
for statistical analysis using two-way ANOVA with two groups 
post hoc tested using Sidak’s multiple comparison testing for each 
concentration. Multiple dose–response curves were compared 
with two-way ANOVA and Tukey’s multiple comparison post hoc 
testing.
resUlTs
Differential activity of the P2X7 receptor 
in human cD8+ and cD4+ T lymphocytes
To study the ATP-induced death of human CD4+ and CD8+ 
T lymphocytes, we treated cells isolated from healthy donors with 
increasing concentrations of the synthetic ATP-analog BzATP. Cell 
death was estimated by measuring LDH activity in the superna-
tant. This enzyme leaks from dying cells as a result of membrane 
permeabilization and can be used as an indirect indicator of 
plasma membrane integrity and cell death. The results showed 
that human CD4+ T lymphocytes released more LDH than CD8+ 
T  lymphocytes (Figure 1A) after 2 h of incubation with BzATP. 
This difference is similar to what has been observed for CD4+ and 
CD8+ T lymphocytes in mice (7, 8). The increase in LDH release 
induced by BzATP could be completely blocked by the P2X7 
receptor antagonist, A740003 (Figure 1B). Cells treated for 24 h 
showed similar levels of LDH release (Figure S2A in Supplementary 
Material), suggesting that cell death occurred during the first 2 h 
after BzATP stimulation. This is consistent with a previous report 
where P2X7 receptor-mediated cell lysis was observed as early as 
15 min after stimulation with ATP in mouse lymphocytes (18).
FigUre 1 | CD4+ and CD8+ T lymphocytes show a differential response to 
P2X7 stimulation. (a) The difference in CD4+ (orange rhomb) and CD8+ 
(purple square) T lymphocyte P2X7 receptor activation with BzATP was 
measured as lactate dehydrogenase (LDH) activity in the supernatant 
following 2 h stimulation. Data are shown as mean ± SEM normalized to 
maximum induced cell death in 1% Triton X-100, n = 5–6 from three 
independent donors. (b) The BzATP response in CD4+ and CD8+ 
T lymphocytes blocked by P2X7 receptor antagonist, A740003. Cells were 
stimulated with 1,000 µM BzATP in combination with various concentrations 
of P2X7 receptor antagonist, A740003, and P2X7 receptor activation was 
measured as the activity of LDH after 2 h. Data are shown as mean ± SEM of 
maximum induced cell death at 1% Triton X-100, n = 11–14 from seven 
independent donors. LDH baseline activity is shown as solid lines for CD4+ 
(orange) and CD8+ (purple) T lymphocytes, respectively.
FigUre 2 | P2X7 levels are equally high in CD4+ and CD8+ T lymphocytes. 
(a) P2RX7 gene expression in human CD4+ and CD8+ T lymphocytes shown 
as ΔCt values normalized to the genes for GAPDH and ACTB (β-actin) from 
18 to 21 independent donors. (b) Western blot showing P2X7 receptor 
signal (75 kDa) from protein lysate of CD4+ (orange) and CD8+ (purple) 
T lymphocytes from five different donors (#1–5). Loading control was β-actin 
(42 kDa).
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similar P2X7 receptor expression in 
human cD4+ and cD8+ T lymphocytes
The higher P2X7 receptor-mediated response in mouse CD4+ 
T  lymphocytes compared to CD8+ T  lymphocytes has been 
explained by differences in expression levels of the P2X7 receptor 
(7, 8). Therefore, P2RX7 gene and protein expression in human 
CD4+ and CD8+ T  lymphocytes were measured. Surprisingly, 
there was no difference in the expression levels of P2RX7 mRNA 
between human CD4+ and CD8+ T  lymphocytes (Figure  2A), 
and the P2X7 receptor protein level was similar or slightly lower 
in CD4+ T lymphocytes compared to that in CD8+ T lymphocytes 
from five different human donors when examined by Western 
blot (Figure 2B). A similar human P2X7 receptor expression was 
previously been found in human CD4+ and CD8+ T lymphocytes 
with flow cytometry (19, 20). This shows that in human individu-
als, the greater P2X7 receptor-induced LDH release from CD4+ 
T lymphocytes following BzATP stimulation is not explained by 
higher P2X7 receptor expression levels.
We, therefore, hypothesized that the differential BzATP 
response in human CD4+ and CD8+ T lymphocytes was due to a 
protective effect of a high P2Y11 receptor expression counteracting 
P2X7 receptor-mediated cell death in CD8+ T lymphocytes. This 
was based on previous findings that P2Y11 receptor stimulation 
mitigated the effect of ATP-induced cell death in PBMCs (12) 
and delayed apoptosis in neutrophils (13). The mRNA expression 
and protein levels of the P2Y11 receptor were indeed found to be 
significantly higher in human CD8+ compared to that in CD4+ 
T lymphocytes (Figures 3A,B) complying with the hypothesis.
immune activation of human cD4+ T 
lymphocytes In Vitro causes Upregulation 
of P2RY11
Immune-activated murine CD4+ T  lymphocytes have lower 
levels of P2X7 receptor and are more resistant to P2X7 receptor-
dependent cell death than their naïve counterparts (21). Therefore, 
the level of P2RX7 and P2RY11 gene expression in human CD4+ 
T lymphocytes following in vitro immune activation was investi-
gated. Over a 3-day period, both P2RX7 and P2RY11 gene expres-
sion levels increased in CD4+ T lymphocytes following immune 
activation. No changes in P2RY11 or P2RX7 gene expression levels 
FigUre 3 | Higher P2Y11 levels in CD8+ T lymphocytes and immune-activated CD4+ T lymphocytes correlate with lower responses to BzATP compared to naïve 
CD4+ T lymphocytes. (a) Left axis: P2RY11 gene expression in human CD4+ and CD8+ T lymphocytes shown as ΔCt values normalized to the genes for GAPDH 
and ACTB (β-actin) from 14 to 18 independent donors. Right axis: mean fluorescence intensity (MFI) as measured by flow cytometry on eight independent donors. 
(b) Western blot membrane with protein lysate of CD4+ (orange) and CD8+ (purple) T lymphocytes from five different donors (#1–5) following stripping and re-blotting 
for P2Y11 signal (33 kDa). Loading control was β-actin (42 kDa) after stripping and re-blotting. (c) ΔCt values for human P2RY11 (green) and P2RX7 (red) gene 
expression over time in naïve and immune-activated CD4+ T lymphocytes. Values were normalized to the genes for B2M and EEF1A1 from three independent 
donors. (D) Lactate dehydrogenase (LDH) activity in the supernatant following 2 h incubation with various concentrations of BzATP of 2-day cultured naïve (filled 
rhomb) or immune-activated (open rhomb) CD4+ T lymphocytes. Data are shown as mean ± SEM of maximum induced cell death at 1% Triton X-100, n = 4–6 from 
three independent donors.
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were found in CD8+ T lymphocytes following immune activation 
(data not shown). In contrast to murine CD4+ T  lymphocytes, 
human CD4+ T lymphocytes did not downregulate P2RX7 gene 
expression upon immune activation. Instead, a higher P2RX7 
level was observed (Figure 3C). Immune-activated CD4+ T lym-
phocytes showed a marked decrease in BzATP-induced LDH 
release compared to naïve cells when tested at day 2 (Figure 3D). 
Clearly, the reduced BzATP response in the human cells was not 
caused by a decrease in P2RX7 expression as shown for murine 
cells. In line with our hypothesis, P2RY11 gene expression was 
more than 10-fold upregulated in human CD4+ T lymphocytes 
following immune activation (Figure  3C), suggesting that in 
humans, the lower P2X7 receptor-mediated LDH release from 
immune-activated CD4+ T lymphocytes is caused by an increased 
P2Y11 receptor expression.
P2Y11 receptor inhibition in human  
T lymphocytes
Currently, the most specific P2Y11 antagonist known is NF340 
that blocks P2Y11 stimulation by BzATP in the dose range of 0.1–
10 µM (22). If the P2Y11 signaling inhibited P2X7 activation, we 
expected that antagonizing the P2Y11 receptor with NF340 would 
increase LDH release. NF340 had, however, no effect on BzATP-
induced P2X7 activity in primary CD4+ and CD8+ T lymphocytes 
when tested in doses ranging from 7.4 to 200 µM (Figure S2B in 
FigUre 4 | P2RY11 silencing in CD8+ T lymphocytes shows increased BzATP-induced cell death following immune activation. (a) Relative P2RY11 gene 
expression changes 24 and 48 h in CD8+ T lymphocytes left untreated (gray) or after transient transfection with non-targeting (NT) (turquoise) or siRNA targeting 
P2RY11 (purple). (b) P2Y11 protein expression measured by flow cytometry count in isotype control (black), NT siRNA (turquoise), NT siRNA immune-activated (red), 
P2RY11-silenced (purple), or P2RY11-silenced immune-activated CD8+ T lymphocytes from a single donor. (c) Mean fluorescence intensity (MFI) from P2Y11 
receptor protein expression measured by flow cytometry on transient transfected CD8+ T lymphocytes. (D) Lactate dehydrogenase (LDH) activity in transiently 
transfected CD8+ T lymphocytes stimulated 2 h with BzATP. Data are shown as mean ± SEM of maximum induced cell death at 1% Triton X-100 following baseline 
correction, n = 5–6 from two independent donors.
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Supplementary Material) on a baseline of 1,000 µM BzATP. We 
worried that the high concentrations of BzATP applied to induce 
significant P2X7 activation would make it impossible to block 
P2Y11 activation with NF340 or any other pathway-interfering 
compound. Therefore, to test the effect of P2Y11 signaling on 
P2X7 cell death, we turned to the use of siRNA.
Transient transfection of CD8+ T  lymphocytes with P2RY11 
siRNA resulted in an almost complete removal of P2RY11 mRNA 
after 24 and 48 h (Figure 4A), but not in CD4+ T lymphocytes 
(data not shown). This decrease was not equally reflected in 
protein expression when examined with a flow cytometer. The 
P2Y11 receptor expression was close to identical between groups 
(Figures 4B,C). This suggested a low turnover of P2Y11 receptor 
on the CD8+ T lymphocytes. Having already found that immune 
activation could increase P2RY11 gene expression in CD4+ 
T  lymphocytes, we tested if immune activation upregulated 
P2Y11 receptor protein in the CD8+ T  lymphocytes. The CD8+ 
T lymphocytes showed two populations with high and low P2Y11 
receptor expressions, respectively (see gating strategy in Figure 
S3 in Supplementary Material). We found that the level of P2Y11 
receptor protein was upregulated following immune activation 
in CD8+ T lymphocytes in the P2Y11high subset (Figure 4C). This 
was not seen in immune-activated CD8+ T  lymphocytes when 
P2RY11 was silenced. Hence, silencing of P2RY11 in human CD8+ 
T lymphocytes decreased P2RY11 gene expression and prevented 
the cells from upregulating P2Y11 receptor protein expression 
following immune activation.
When the transfected CD8+ T  lymphocytes were stimulated 
with BzATP, the immune-activated P2RY11-silenced CD8+ 
T  lymphocytes had a significantly higher LDH release than 
immune-activated non-silenced cells (Figure 4D). This suggests 
that following immune activation, the T lymphocytes upregulate 
FigUre 5 | P2X7-mediated cell death and pore formation are lower when cells are cotransfected with P2RY11. Top row: the activity of lactate dehydrogenase 
(LDH) in the supernatant after 2 h in human embryonic kidney-293 (HEK-293) cells transiently transfected with vectors expressing purinergic receptors. Cells were 
stimulated with (a) increasing doses of BzATP, n = 5–6 from three experimental runs or (b) 1,000 µM BzATP in combination with various concentrations of P2X7 
receptor antagonist, A740003, n = 6–8 from five experimental runs. Data are shown as mean ± SEM of maximum-induced cell death by 1% Triton X-100. LDH 
baseline activity is shown as solid lines for eGFP + empty vector (black), P2RX7 + empty vector (red), and P2RX7 + P2RY11 (blue), respectively. Bottom row: 
GripTite cells transiently transfected with vectors expressing purinergic receptors were stimulated with various concentrations of BzATP to induce pore formation 
measured as YO-PRO-1 fluorescent dye uptake. Cells were stimulated with (c) increasing doses of BzATP, n = 12–29 from nine experimental runs or (D) BzATP 
and P2X7 receptor antagonist, A740003, n = 6–15 from five experimental runs. Data are shown as mean ± SEM.
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P2Y11 receptor, making them more resistant to cell death and that 
silencing P2RY11 prevents the cells from using this protective 
mechanism.
P2RY11 expression counteracts P2X7 
receptor-Driven cell Death
Next, we studied the mechanism behind how P2Y11 receptor 
interfered with P2X7 receptor-driven membrane permeabiliza-
tion and consecutive cell death in cell cultures overexpressing 
P2RY11 and P2RX7 separately or in combination. The cells were 
treated with various doses of BzATP, and P2X7 receptor-induced 
cell death was measured by LDH release into the supernatant 
after 2  h stimulation. As expected, cells overexpressing P2RX7 
displayed a significant increase in LDH release compared to 
control cells transfected with an empty vector (Figure 5A). This 
effect was mediated by the P2X7 receptor, as LDH release was 
completely inhibited by adding the P2X7 receptor antagonist 
A740003 (Figure  5B). Interestingly, coexpression of P2RY11 
prevented the BzATP-induced LDH release. This complies with 
our hypothesis that the P2Y11 receptor protects against P2X7 
receptor-driven cell death. To rule out that the inhibition of 
LDH release was caused by a lower P2RX7 expression in the 
cotransfected cells, the gene expression levels for P2RX7 and 
P2RY11 were measured in the transfected cells. Coexpression of 
P2RY11 did not result in a decreased gene expression of P2RX7 
(Figure S1C in Supplementary Material).
P2RY11 expression counteracts P2X7 
receptor-Driven Pore Formation 
independent of calcium signaling
Membrane permeabilization and LDH release as a response to 
ATP stimulation are believed to be caused by a pore-forming action 
of the P2X7 receptor (23). We, therefore, tested the hypothesis that 
P2RY11 coexpression interfered with membrane permeabilization 
and LDH release observed in BzATP-treated cells by preventing 
FigUre 6 | P2X7-mediated Ca2+ response is still present when cells are 
cotransfected with P2RY11. Normalized calcium response measured by 
Fluo-4 following stimulation with various concentrations of BzATP of 
transiently transfected GripTite cells. Data are shown as mean ± SD, n = 9 
from three independent experiments. Dose–response curves for P2RX7 (red) 
and P2RY11 (green) were fitted to a sigmoidal curve and cotransfected 
P2RX7 + P2RY11 to a biphasic sigmoidal curve. Vertical dashed lines 
represent EC50 values for respective curves and 95% confidence intervals in 
colored shades. See text for details.
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P2X7 receptor pore formation. Cells overexpressing P2RX7 were 
stimulated with BzATP, and YO-PRO-1 uptake was quantified 
as a measure of pore formation (Figure 5C). YO-PRO-1 enters 
the cell through the P2X7 receptor pore and becomes fluorescent 
upon DNA binding. A significant P2X7 receptor pore formation 
was observed at lower concentrations of BzATP than LDH release. 
The BzATP-induced increase in YO-PRO-1 signal was exclusively 
caused by dye uptake through the P2X7 receptor pore, as the 
P2X7 receptor antagonist A740003 completely removed the effect 
of BzATP (Figure 5D). At concentrations above 500 µM BzATP, 
the YO-PRO-1 dye signal from P2RX7 transfected cells decreased 
(data not shown) most likely due to cell detachment following 
cell death. Coexpression of P2RY11 completely inhibited pore 
formation in P2RX7 expressing cells (Figure 5C).
By contrast, calcium signaling through P2X7 receptor appeared 
unaffected as cells expressing both P2RX7 and P2RY11 showed a 
biphasic response to BzATP with EC50 values equal to their respec-
tive single-transfected counterparts (Figure 6). Values from fitted 
sigmoidal curves were P2RY11 EC50 =  0.29 (0.23–0.36) μM and 
P2RX7 EC50 = 53 (47–61) μM, respectively, and the values for the 
biphasic sigmoidal dose–response curve for P2RX7 + P2RY11 were 
EC50 = 0.56 (0.35–1.05) μM and EC50 = 82 (54–132) μM. This sug-
gested that P2RY11 expression interfered with P2X7 receptor pore 
formation independent of calcium signaling.
P2RY11-Mediated inhibition of P2X7 
receptor Dye Uptake Was not caused  
by P2Y11 receptor signaling
The P2Y11 receptor is a GPCR that signals via both Gs and Gq to 
activate the adenylyl cyclase and the phosphate inositol pathway 
(9, 10). We next asked whether the block of pore formation was 
caused by P2Y11 receptor signaling through Gs and/or Gq path-
ways. However, as the BzATP concentration needed to activate 
the P2X7 receptor at the same time saturated the P2Y11 receptor, 
it was not possible to activate P2X7 receptor while at the same 
time inhibiting P2Y11 receptor signaling (Figure 6). Instead, we 
tested a non-signaling P2Y11 receptor mutant in the cotransfec-
tion system. Among other amino acids, arginine 307 in the P2Y11 
receptor has been predicted to be involved in ATP binding, 
interacting with the phosphate Pα moiety (24). This has been con-
firmed experimentally by mutational analysis, revealing inactiva-
tion of the receptor as measured by intracellular calcium release 
(24). Therefore, vectors expressing wild-type P2Y11 receptor and 
C919T-mutated P2RY11 sequence resulting in the Arg307 being 
substituted with a tryptophan were tested. The mutated P2Y11 
receptor was completely non-signaling as expected with regard to 
both calcium and cAMP signaling (Figures 7A,B). Coexpression 
of either P2Y11 or P2Y11 C919T receptors showed identical inhibi-
tion of P2X7 receptor YO-PRO-1 dye uptake, demonstrating that 
the P2Y11 receptor-induced inhibition of P2X7 receptor function 
is independent of signaling (Figure 7C).
DiscUssiOn
This study provides evidence that human CD4+ and CD8+ 
T lymphocytes display differential responses to BzATP-induced 
P2X7 receptor activation similar to what has been seen for mouse 
lymphocytes. The difference in P2X7 receptor activity could not 
be explained by different levels of P2X7 receptor expression. This 
is consistent with previous studies showing identical surface 
P2X7 receptor expression levels in human lymphocyte subtypes 
from healthy donors (19, 20). Furthermore, we showed that 
in vitro immune-activated human CD4+ T lymphocytes did not 
significantly change P2RX7 gene expression but that the cells 
nevertheless displayed a decreased LDH release following BzATP 
stimulation. By contrast, immune-activated CD4+ T lymphocytes 
showed a marked decrease in BzATP response. Clearly, human 
T  lymphocytes have a different strategy for regulating P2X7 
receptor activity than by transcriptional regulation of the P2RX7 
gene as in mice.
Instead, we hypothesized that another ATP-selective receptor, 
the P2Y11 receptor, regulates ATP response in human T lympho-
cytes. Indeed, P2RY11 gene expression was significantly higher 
in human CD8+ T  lymphocytes compared to that in CD4+ 
T lymphocytes consistent with the hypothesis that higher levels 
of the P2Y11 receptor reduce cell death following P2X7 receptor 
stimulation. We further observed that P2Y11 receptor was upregu-
lated in T lymphocytes upon stimulation and that preventing this 
by siRNA treatment caused the immune-activated CD8+ T lym-
phocytes to become more vulnerable toward BzATP-induced 
cell death.
To investigate the possible interaction between the P2X7 recep-
tor and P2Y11 receptor, a model system in HEK-293 cells transiently 
overexpressing the purinergic receptors was established. Two dif-
ferent end points for P2X7 receptor pore formation (LDH release 
and YO-PRO-1 dye uptake) were tested, and it was found that the 
presence of P2Y11 receptor inhibited P2X7 receptor pore formation 
in both assays; by contrast, P2Y11 receptor did not seem to interfere 
FigUre 7 | The effect of P2Y11 on P2X7-mediated pore formation is not 
dependent on P2Y11 signaling. Stimulation with various concentrations of 
BzATP of transiently transfected GripTite cells expressing empty vector 
(black), P2RY11 (closed green square), or P2RY11 C919T (open green 
square) vector in (a) calcium assay measured by Fluo-4, data are shown 
as mean ± SEM, n = 3,6 from 1 to 2 independent runs. (b) cAMP response, 
data are shown as mean ± SEM, n = 3,6 from 1 to 2 independent runs. (c) 
YO-PRO-1 dye uptake as a measure of P2X7 receptor pore formation in cells 
transfected with P2RX7 + empty vector (red), P2RX7 + P2RY11 (half-open 
blue triangle), and P2RX7 + P2RY11 C919T (open blue triangle). Data are 
shown as mean ± SEM, n = 9 from three independent runs. Part of data was 
previously published by Ref. (25).
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with calcium signaling following P2X7 receptor activation. This 
inhibition was not caused by downstream signaling from the P2Y11 
receptor as demonstrated by using a loss-of-function mutant of the 
P2Y11 receptor.
Taken together, our results demonstrate that pore formation 
and cell death following P2X7 receptor activation are controlled 
by factors other than P2X7 receptor expression levels alone. One 
such factor is a P2Y11 receptor, which is particularly interesting 
as the P2Y11 receptor is also stimulated by ATP and BzATP. The 
difference observed in CD4+ and CD8+ T  lymphocytes in cell 
death response following BzATP stimulation is therefore likely 
to be explained by differences in P2Y11 receptor expression levels 
and not by P2X7 receptor levels.
There are many possible ways in which P2RY11 coexpression 
might interfere with P2X7 receptor pore formation. The exact 
mechanism for P2X7 receptor pore formation is still debated, 
but most literature is based on a two-conformation model in 
which the P2X7 receptor homo- or hetero-trimerizes upon 
ligand binding to form a cation channel and at long-lasting 
activation changes conformation into a larger pore (4). In our 
overexpression system, P2RY11 in the transfected cells might 
block the normal processing and/or trafficking of the P2X7 
receptor. P2Y11 receptor inhibition of P2X7 receptor surface 
expression might also occur in human lymphocytes that have 
been suggested to retain P2X7 receptor intracellularly under 
normal conditions (6, 26). Still, cells transfected with both 
P2RX7 and P2RY11 showed a biphasic response to BzATP in 
calcium-signaling assay showing that P2X7 receptor was present 
on the cell surface and capable of signaling as an ion channel.
The P2Y11 receptor might interfere directly with the P2X7 
receptor through steric interaction in the membrane preventing 
pore formation. It could also indirectly interfere with other pro-
cesses necessary for P2X7 receptor signaling such as pannexin-1 
(27, 28) or P2× 4 receptor (4). Other Gq-coupled P2Y receptor 
subtypes together with the P2Y11 receptor have been reported 
to interfere with ion channel function by interactions involving 
the C-terminal and the third transmembrane domain of the P2Y 
receptors (29, 30). This suggests that P2X7 receptor inhibition 
in human T  lymphocytes could also be caused by other P2Y 
receptors. In retinal rat microvessels, the P2X7 receptor pore 
formation was found negligible because ATP also activated P2Y4 
receptors and preventing P2X7 receptor pores from forming (31). 
It is possible that P2Y11 receptor in human T lymphocytes offers 
a species-specific mechanism for regulating immune cell death.
Likewise, P2Y11 receptors might also modulate other P2X 
receptors than the P2X7 receptor. It has, for instance, been shown 
that P2× 1 receptor signaling is changed when coexpressed with 
P2Y1 or P2Y2 receptors (32). Together, this is indicative of a 
complex network of interactions between purinergic receptors 
developed for fine-tuning of their many functions.
Regulation of ion channels through G-protein interaction 
is a well-documented phenomenon. An example is G-protein-
activated inwardly rectifying K+ channels modulated by the Gβγ 
subunit (33). In addition, ion channels can also be indirectly 
modulated by second messengers such as seen for L-type cal-
cium channels in the heart that are stimulated by cAMP (34). 
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FigUre s1 | (a) Normalized calcium (left axis) and cyclic adenosine 
monophosphate (cAMP) (right axis) responses in GripTite cells expressing 
P2RY11 (filled square) and P2RY11-mCherry (half-open square), respectively, 
when stimulated with BzATP. Part of data was previously published (Degn et al., 
2017, Brain) and is shown as mean ± SEM, n = 1–2. (b) Relative fold change in 
P2RY11 (green) and P2RX7 (red) gene expression from human embryonic 
kidney-293 (HEK-293) and GripTite cells transfected with vectors encoding the 
two purinergic receptors. Data are shown as mean ± range, n = 2–3. Relative 
fold changes were calculated using the ΔΔCt approach and genes for β-actin 
and GAPDH as housekeeping genes. Control represents eGFP + empty vector 
and empty vector-transfected HEK-293 and GripTite cells, respectively.
FigUre s2 | (a) Percentage of lactate dehydrogenase (LDH) activity in medium 
from CD4+ (orange rhomb) and CD8+ (purple square) T lymphocytes after 24 h 
stimulation with various concentrations of BzATP. Data are shown as 
mean ± SEM, n = 8–9 from three independent donors relative to maximum 
induced cell death by 1% Triton X-100. (b) Percentage of LDH activity in 
supernatant from CD4+ (orange rhomb) and CD8+ (purple square) T lymphocytes 
following incubation with 1,000 µM BzATP and P2Y11 antagonist, NF340. Data 
were normalized to maximum cell death induced by 1% Triton X-100 with control 
values labeled C. Data are shown as mean ± SEM from two independent 
donors.
FigUre s3 | Gating strategy for P2Y11 detection on CD8+ T lymphocytes by 
flow cytometry.
Cross-talk between ion channels and GPCRs sharing the same 
ligand has also been observed for GABAB receptors (GPCR) that 
enhance GABAA (ligand-gated ion channel) currents through a 
yet unidentified mechanism (35, 36).
In conclusion, our study demonstrates that the P2Y11 receptor is 
capable of interfering with P2X7 receptor pore formation and thus 
preventing cell death through a mechanism that does not involve 
signaling from the P2Y11 receptor. We suggest that this mechanism 
explains the decreased response in naïve human CD8+ T lympho-
cytes to extracellular ATP and that it also prevents P2X7-induced 
cell death in immune-activated CD4+ and CD8+ T lymphocytes.
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